170 related articles for article (PubMed ID: 29611211)
1. A predictive probability interim design for phase II clinical trials with continuous endpoints.
Liu M; Dressler EV
Stat Med; 2018 May; 37(12):1960-1972. PubMed ID: 29611211
[TBL] [Abstract][Full Text] [Related]
2. Optimal futility stopping boundaries for binary endpoints.
Freitag MM; Li X; Rauch G
BMC Med Res Methodol; 2024 Mar; 24(1):80. PubMed ID: 38539108
[TBL] [Abstract][Full Text] [Related]
3. An extension of Bayesian predictive sample size selection designs for monitoring efficacy and safety.
Teramukai S; Daimon T; Zohar S
Stat Med; 2015 Sep; 34(22):3029-39. PubMed ID: 26038148
[TBL] [Abstract][Full Text] [Related]
4. A predictive probability design for phase II cancer clinical trials.
Lee JJ; Liu DD
Clin Trials; 2008; 5(2):93-106. PubMed ID: 18375647
[TBL] [Abstract][Full Text] [Related]
5. Monitoring futility and efficacy in phase II trials with Bayesian posterior distributions-A calibration approach.
Kopp-Schneider A; Wiesenfarth M; Witt R; Edelmann D; Witt O; Abel U
Biom J; 2019 May; 61(3):488-502. PubMed ID: 30175405
[TBL] [Abstract][Full Text] [Related]
6. An optimal Bayesian predictive probability design for phase II clinical trials with simple and complicated endpoints.
Guo B; Liu S
Biom J; 2020 Mar; 62(2):339-349. PubMed ID: 31402481
[TBL] [Abstract][Full Text] [Related]
7. Mixed response and time-to-event endpoints for multistage single-arm phase II design.
Lai X; Zee BC
Trials; 2015 Jun; 16():250. PubMed ID: 26037094
[TBL] [Abstract][Full Text] [Related]
8. Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis.
Smith CL; Jin Y; Raddad E; McNearney TA; Ni X; Monteith D; Brown R; Deeg MA; Schnitzer T
Pharm Stat; 2019 Jan; 18(1):39-53. PubMed ID: 30321909
[TBL] [Abstract][Full Text] [Related]
9. A flexible multi-stage design for phase II oncology trials.
Tan MT; Xiong X
Pharm Stat; 2011; 10(4):369-73. PubMed ID: 22328328
[TBL] [Abstract][Full Text] [Related]
10. Optimal continuous-monitoring design of single-arm phase II trial based on the simulated annealing method.
Chen N; Lee JJ
Contemp Clin Trials; 2013 May; 35(1):170-8. PubMed ID: 23545075
[TBL] [Abstract][Full Text] [Related]
11. Optimal and minimax three-stage designs for phase II oncology clinical trials.
Chen K; Shan M
Contemp Clin Trials; 2008 Jan; 29(1):32-41. PubMed ID: 17544337
[TBL] [Abstract][Full Text] [Related]
12. Designs for phase II trials allowing for a trade-off between response and toxicity.
Conaway MR; Petroni GR
Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
[TBL] [Abstract][Full Text] [Related]
13. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
Cellamare M; Sambucini V
Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
[TBL] [Abstract][Full Text] [Related]
14. New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.
Thall PF; Simon RM; Estey EH
J Clin Oncol; 1996 Jan; 14(1):296-303. PubMed ID: 8558211
[TBL] [Abstract][Full Text] [Related]
15. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian adaptive dose selection procedure with an overdispersed count endpoint.
Pozzi L; Schmidli H; Gasparini M; Racine-Poon A
Stat Med; 2013 Dec; 32(28):5008-27. PubMed ID: 24022748
[TBL] [Abstract][Full Text] [Related]
17. Two-stage phase II oncology designs using short-term endpoints for early stopping.
Kunz CU; Wason JM; Kieser M
Stat Methods Med Res; 2017 Aug; 26(4):1671-1683. PubMed ID: 26037529
[TBL] [Abstract][Full Text] [Related]
18. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
Schmidli H; Bretz F; Racine-Poon A
Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
[TBL] [Abstract][Full Text] [Related]
19. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
Schmidt R; Burkhardt B; Faldum A
Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
[TBL] [Abstract][Full Text] [Related]
20. Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing's sarcoma.
Dutton P; Love SB; Billingham L; Hassan AB
Stat Methods Med Res; 2018 May; 27(5):1451-1463. PubMed ID: 27587590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
